Ellevest Inc’s Ocular Therapeutix OCUL Stock Holding History

Ellevest Inc’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7	Closed	–	–	1366
2021 Q1	$0	Hold	7	–	–	﹤0.01%	1325
2020 Q4	$0	Buy	+7	New	+$104	﹤0.01%	1306

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Ellevest Inc's OCUL Position: Q2 2021 in Review

Ellevest Inc sold out of Ocular Therapeutix (OCUL) in Q2 2021, closing a stake of 7 shares.

Ellevest Inc first reported a position in OCUL in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q1 2021. 149 funds tracked by Wall St. Rank hold OCUL as of Q2 2021.

Ellevest Inc reported no remaining Ocular Therapeutix position as of Q2 2021 after selling out during the quarter.
Ellevest Inc sold 7 Ocular Therapeutix shares in Q2 2021.
Ellevest Inc first reported a position in Ocular Therapeutix in Q4 2020 and held it in 2 quarters.
Ellevest Inc's Ocular Therapeutix position peaked at $0 in Q1 2021.
149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2021.

Based on Ellevest Inc's 13F filing for Q2 2021, filed 13 Jul 2021.